Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1Myofibroma 1Castration-resistant Prostate Cancer, Advanced Breast Cancer 1Breast Neoplasms 1

Interventions

Misoprostol 5Uterine Myomectomy 3Saline Solution 3relugolix 2dienogest 2carbetocin 2Uterine Artery Embolization 2Tranexamic Acid 2Tourniquets 2Lidocaine 2Leuprolide 2Ascorbic Acid 2ulipristal 1telapristone acetate 1ramosetron 1pirfenidone 1estradiol, norethindrone drug combination 1Vasopressins 1Triptorelin Pamoate 1Tablets 1Sodium Chloride 1Sevoflurane 1Respiration, Artificial 1Remifentanil 1Propofol 1Population Groups 1Oxytocin 1Nuclear Receptor Subfamily 4, Group A, Member 2 1Morcellation 1Methylergonovine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myofibroma × LFA102 monoclonal antibody × Clear all
NCT01338831 2020-12-17

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

Novartis

Phase 1 Completed
73 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms, Myofibroma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡